Knowledge of Living Will in Patients With Rheumatic Diseases

National Institute of Medical Sciences and Nutrition, Salvador Zubiran

Status: Enrolling

Conditions: Rheumatic Disorder

Treatments: Other: Health Assessment Questionnaire (HAQ); Other: Perceptions of Health Outcomes Questionnaire; Other: Rheumatic disease comorbidity index; Other: Brief Resilient Coping Scale; Other: Depression, Anxiety and Stress Scale (DASS-21); Other: WHOQOL-BREF; Other: Routine assessment of patient index data 3 (RAPID-3); Other: Living will questionnaire

Study type: Observational

Funder types: Other

Identifiers

NCT05676359

IRE-4312

Details and patient eligibility

About

The living will is a legal document derived from a communication and deliberation process, medical ethical aspect, currently regulated in Mexico by the General Health Law and the Health Law of Mexico City.

Knowledge of living will in the population with chronic diseases, including rheumatic diseases, has been little addressed. Most patients do not know what the living will document is, so they do not carry it out and others, despite knowing it, have a passive attitude toward doing it.

Full description

A study will be carried out on patients with rheumatic diseases and healthy family controls. Patients will be selected from those attending the Department of Immunology and Rheumatology in Mexico City outpatient department, including consecutive cases.

The patients will be assessed for their quality of life and disability. Patients and controls will be evaluated on the knowledge of living will, their perceptions about specific health outcomes, sociodemographic characteristics, comorbidities, and psychiatric pathology.

Enrollment: 157 estimated patients

Sex: All

Ages: 18 to 100 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

Cases

• Patients with a rheumatic disease diagnostic by a rheumatologist
• Patients with rheumatic diseases attending the Department of Immunology and Rheumatology in Mexico City outpatient department
• Patients who agree to participate in the study, who complete and sign the informed consent Controls
• Relative of a patient with rheumatic diseases of the same sex and age ± 5 years, without known rheumatic and/or chronic disease and without the use of pharmacological treatment for more than 7 days during the month before study entry.

Exclusion criteria

Cases

• Patients with severe diseases or in palliative care by a rheumatologist

Controls

• Withdrawal of the study

Trial design

157 participants in 2 patient groups

Cases

Description:

Patients with rheumatic diseases from the outpatient clinic at a tertiary care level in Mexico City

Treatment:

Other: Perceptions of Health Outcomes Questionnaire

Other: Rheumatic disease comorbidity index

Other: WHOQOL-BREF

Other: Brief Resilient Coping Scale

Other: Depression, Anxiety and Stress Scale (DASS-21)

Other: Health Assessment Questionnaire (HAQ)

Other: Living will questionnaire

Other: Routine assessment of patient index data 3 (RAPID-3)

Controls

Description:

Two patients´ relatives of the same sex, age ± five years and who are known to be healthy

Treatment:

Other: Perceptions of Health Outcomes Questionnaire

Other: Rheumatic disease comorbidity index

Other: WHOQOL-BREF

Other: Brief Resilient Coping Scale

Other: Depression, Anxiety and Stress Scale (DASS-21)

Other: Health Assessment Questionnaire (HAQ)

Other: Living will questionnaire